Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
FOMX was delisted on the 6th of March, 2020.
56 hedge funds and large institutions have $125M invested in Foamix Pharmaceuticals Ltd. Ordinary Shares in 2018 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 20 increasing their positions, 12 reducing their positions, and 7 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 12
41% more call options, than puts
Call options by funds: $266K | Put options by funds: $188K
14% more capital invested
Capital invested by funds: $110M → $125M (+$15.1M)
0% more funds holding
Funds holding: 56 → 56 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$15.1M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.99M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$3.14M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$2.51M |
| 5 |
SAM
Senzar Asset Management
New York
|
+$347K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.6M |
| 2 |
Millennium Management
New York
|
-$2.21M |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$1.07M |
| 4 |
AC
Ascend Capital
Orinda,
California
|
-$1.04M |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$666K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Bank of America
Charlotte,
North Carolina
| $20K | -$24.7K | -4,799 | -55% |
|
52
Victory Capital Management
San Antonio,
Texas
| $18K | – | – | – |
|
53
Royal Bank of Canada
Toronto,
Ontario, Canada
| $17K | -$13.3K | -2,584 | -43% |
|
|
LTFS
54
Ladenburg Thalmann Financial Services
Miami,
Florida
| $5K | – | – | – |
|
|
CG
55
Cutler Group
San Francisco,
California
| $2K | +$2.57K | +500 | New |
|
56
Daiwa Securities Group
Tokyo,
Japan
| $1K | – | – | – |
|
|
SCM
57
Stonepine Capital Management
Bend,
Oregon
| – | -$666K | -129,756 | Closed |
|
|
EIM
58
Essex Investment Management
Boston,
Massachusetts
| – | -$401K | -78,136 | Closed |
|
|
IBT
59
International Biotechnology Trust
London,
United Kingdom
| – | -$324K | -63,202 | Closed |
|
|
PCM
60
Prelude Capital Management
New York
| – | -$261K | -50,915 | Closed |
|
|
EMG
61
ETF Managers Group
Summit,
New Jersey
| – | -$160K | -32,021 | Closed |
|
|
ARTA
62
A.R.T. Advisors
New York
| – | -$104K | -20,321 | Closed |
|
|
HIIFS
63
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
| – | -$14K | -2,707 | Closed |
|
FOMX Hedge Fund Activity: Q2 2018 in Review
56 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) for Q2 2018, worth a combined $125M — up 14% from $110M a quarter earlier.
Fund positioning in FOMX was balanced in Q2 2018: 7 funds opened new positions, 7 closed out, 20 added to existing stakes and 12 trimmed.
The largest buyer was OrbiMed, adding an estimated $15.1M. The largest seller was Opaleye Management, cutting an estimated $3.6M.
- 56 institutional investors held Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $125M of Foamix Pharmaceuticals Ltd. Ordinary Shares stock for Q2 2018, up 14% quarter-over-quarter.
- 7 funds opened new Foamix Pharmaceuticals Ltd. Ordinary Shares positions in Q2 2018 and 7 closed out, a net change of 0 holders.
- The largest Foamix Pharmaceuticals Ltd. Ordinary Shares buyer in Q2 2018 was OrbiMed, an estimated $15.1M added.
- The largest Foamix Pharmaceuticals Ltd. Ordinary Shares seller in Q2 2018 was Opaleye Management, an estimated $3.6M sold.
Based on aggregated 13F filings for Q2 2018.